The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Open accessAbstract
The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial immune-regulatory roles played by MHC-I molecules, the abnormal modulation of MHC-I expression and function could be hijacked by tumor cells to escape the immune surveillance and attack, thereby promoting tumoral progression and impairing the efficacy of cancer immunotherapy. Here we reviewed and discussed the recent studies and discoveries related to the MHC-I molecules and their multidirectional functions in the development of cancer, mainly focusing on the interactions between MHC-I and the multiple participators in the tumor microenvironment and highlighting the significance of targeting MHC-I for optimizing the efficacy of cancer immunotherapy and a deeper understanding of the dynamic nature and functioning mechanism of MHC-I in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It is well-known that T cells recognize the peptide-loaded major histocompatibility complex (pMHC) presented by antigen-presenting cells via the TCRs, thereby triggering the subsequent immune response to kill cancerous or infectious cells [132].”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47 · cited 1×
“Notably, negative MHC-I might activate NK cells, which then act as the main cause of CAR-T cell death [141].”
BackgroundRetractedMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“In addition, genetic mutations in B2M, resulting in the formation of defective HLA, may also be associated with acquired resistance to ICB treatment [110, 111].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“They identified the mutation as being enriched in numerous cancer types [46].”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 2×
“In addition, genetic mutations in B2M, resulting in the formation of defective HLA, may also be associated with acquired resistance to ICB treatment [110, 111].”
BackgroundAn immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 1×
“Tumor neoanti-gen vaccination can enhance the anti-tumor immune response, notably neoantigen-specific T cells [126–128].”
BackgroundIn search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“The majority of researchers believe that MHC-I-deficient cancer cells are killed by NK cells because they cannot bind inhibitory receptors on NK cells [145].”
BackgroundPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · cited 2×
“Notably, MHC-I could be upregulated by radiation, which makes it possible to improve antigen presentation and increase the recognition capacity and cytotoxicity of T cells [149–152].”
BackgroundSaxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Research works printed but not linked: 1
- van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andre P, et al. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer vaccines. Cell. 2018;175:1744. · DOI · Paper page
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Single-cell sequencing to multi-omics: technologies and applications
Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., & Yang, R. (2024) · Biomarker Research · doi:10.1186/s40364-024-00643-4 · Cited by 222
“It is well-known that T cells recognize the peptide-loaded major histocompatibility complex (pMHC) presented by antigen-presenting cells via the TCRs, thereby triggering the subsequent immune response to kill cancerous or infectious cells [132].”
BackgroundSelf-citationCancer stem cells and niches: challenges in immunotherapy resistance
Pan, Y., Yuan, C., Zeng, C., Sun, C., Xia, L., Wang, G., Chen, X., Zhang, B., Liu, J., & Ding, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02265-2 · Cited by 122
“These MHC-I molecules then travel to the cell surface, where they present the tumor-derived peptides to T cells [50, 51].”
The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Li, J., Chen, P., & Ma, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00549-9 · Cited by 120
“After processing, peptides derived from tumor cells are presented via MHC class I molecules, crucial for activating CD8 + cytotoxic T cells [113, 114].”
MethodXiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 95
“The MHC-I/LILRB1 signaling axis represents a “do not eat me” signaling pathway, where inhibition of LILRB1 or MHC-I could significantly enhance the phagocytic activity against tumor cells [8, 9, 24].”
Background
Metadata
- Authors
- Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R.
- Affiliations
- Nanjing Drum Tower Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Fujian Medical University (CN)
- Corresponding author
- Guo, Hongqian
- Yang, Rong
- Venue
- Molecular Cancer
- Published
- 2023-12-02
- Volume
- 22
- Issue
- 1
- Pages
- 194-194
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC10693139
- OpenAlex
- W4389266107
- Cited by
- 223
- References
- 163
- Citations by year
- 2026: 78 · 2025: 109 · 2024: 34 · 2023: 2
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81772710, 82172691)
- Nanjing Science and Technology Development Key Project (YKK19011)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- MHC class I, cancer immunotherapy, tumor immune evasion, tumor microenvironment, peptide presentation, tumor progression, immune checkpoint blockade
- MeSH terms
- Cell Membrane, Humans, Immunotherapy, Neoplasms, Histocompatibility Antigens Class I, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. https://app.cochat.ai/papers/10.1186/s12943-023-01899-4
- The paper
- Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023). Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Molecular Cancer. https://doi.org/10.1186/s12943-023-01899-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

